Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
underactive bladder syndrome epidemiology forecast

Underactive Bladder (UAB) Syndrome– Epidemiology Forecast – 2034

Published Date : 2025

Pages : 70

Region : United States, Japan, China, EU4 & UK

Summary
TOC Table of Content
LOT
- Sample Request

underactive bladder syndrome epidemiology forecast

Key Highlights

UAB presents with variable bladder contractility, voiding patterns, and comorbid conditions, highlighting the need for stratified or personalized therapeutic approaches. Patients experience difficulty with bladder emptying, incontinence, and frequent catheterization, creating a significant impact on independence and quality of life (QoL).
Limited data exist on UAB prevalence, with current literature offering few estimates; existing studies highlight significant gaps and limitations in understanding the disease’s epidemiology. Among the 7MM + China, China accounted for the highest diagnosed prevalent cases of UAB with more than 11 million in 2024, which is expected to rise to by 2034.
Men are more frequently affected by UAB due to a higher prevalence of prostate-related issues, such as benign prostatic hyperplasia, which can obstruct bladder outflow and impair bladder muscle function.
Prevalence estimates are derived from patients aged 40 years and above, underscoring the progressive decline in detrusor contractility that elevates UAB incidence in this age group.
A higher diagnostic yield is observed in postoperative populations, particularly following pelvic, urologic, and spinal surgeries, where detrusor underactivity frequently emerges as a secondary complication.
UAB remains clinically under-recognized, often misdiagnosed as an overactive bladder due to overlapping symptoms. Limited clinician awareness and inconsistent diagnostic criteria delay accurate detection, leading to inappropriate management and worsening patient burden.

DelveInsight’s “Underactive Bladder (UAB) Syndrome– Epidemiology Forecast – 2034” report delivers an in-depth understanding of Underactive Bladder (UAB), historical and forecasted epidemiology of Underactive Bladder (UAB) in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and China.

Geography Covered

The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
China

Study Period: 2020–2034

Underactive Bladder (UAB) Disease Understanding

Underactive Bladder (UAB) Overview

Underactive bladder (UAB) is a condition marked by diminished bladder contractions, leading to incomplete emptying. Its causes range from nerve damage and diabetes to aging and specific medications. Risk factors include neurological disorders, pelvic surgeries, and chronic diseases. The burden of UAB is profound, encompassing recurrent urinary tract infections, potential kidney damage, and significantly diminished quality of life due to urinary retention and frequent catheterization. Early diagnosis and targeted management are crucial to alleviating these impacts and improving patient outcomes.

Underactive Bladder (UAB) Diagnosis

Diagnosing UAB involves urodynamic testing, bladder scans, and patient history evaluations to assess bladder function, identify incomplete emptying, and determine underlying causes.

Accuracy in diagnosis of UAB remains a significant challenge within the clinical setting, leading to widespread misdiagnosis or underdiagnoses. UAB is often erroneously interpreted as BOO or overactive bladder OAB due to overlapping symptoms. This diagnostic ambiguity significantly hampers the identification and appropriate management of UAB, resulting in inadequate treatment for many patients.

The overlap in clinical presentation such as urinary frequency, urgency, and hesitancy between UAB, BOO, and OAB contributes to this confusion. Healthcare providers may mistakenly attribute symptoms to more commonly diagnosed conditions like BOO or OAB, overlooking the possibility of UAB. This misinterpretation is compounded by the lack of standardized diagnostic criteria and tools specifically tailored for UAB, further exacerbating the issue.

Further details related to country-based variations are provided in the report

Underactive Bladder (UAB) Epidemiology

As the market is derived using the patient-based model, the Underactive Bladder (UAB) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of LUTS, total diagnosed prevalent cases of UAB, etiology-specific diagnosed prevalent cases of UAB, and total treated cases of UAB in the 7MM + China covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China from 2020 to 2034.

As per DelveInsight’s estimations, the total diagnosed prevalent cases of LUTS in the 7MM + China were approximately 67 million cases in 2024 and are projected to increase during the forecast period. The anticipated rise in prevalent cases of moderate to severe LUTS in the US is attributed to an aging population, increased prevalence of obesity, and sedentary lifestyles.
The total diagnosed prevalent cases of UAB in the United States were approximately 1,900 thousand in 2024. Given the increasing prevalence of risk factors, increased awareness and diagnosis, higher occurrence of chronic conditions, improved healthcare access, and enhanced data collection for UAB in the United States population, the diagnosed prevalence is estimated to increase during the forecast period (2025–2034).
Prevalence estimates are derived from patients aged 40 years and above, underscoring the progressive decline in detrusor contractility that elevates UAB incidence in this age group.
Among the 7MM, EU4 and the UK accounted for nearly 13% diagnosed prevalent cases of Underactive Bladder (UAB) in 2024.
In 2024, neurogenic causes accounted for the majority of UAB cases in Japan at approximately 85%, followed by idiopathic etiologies, while myogenic impairment due to detrusor muscle dysfunction represented a smaller proportion. The remaining cases were linked to other factors, including post-surgical and medication-related causes.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on UAB evolving epidemiology landscape, patient reliance on conventional therapies, patient’s therapy switching acceptability, and drug uptake along with challenges related to accessibility, include Massachusetts General Hospital, Boston; Department of Urologic Surgery, Nashville, Tennessee, US; Department of Child and Adolescent Psychiatry, Saarland University Hospital, Homburg, Germany; Southmead Hospital, United Kingdom; Department of Urology, University Hospital of Rennes, Rennes, France; Department of Urology, Sakurajyuji Hospital, Japan, and others.

Delveinsight’s analysts connected with 10+ KOLs to gather insights, however, interviews were conducted with 5+ KOLs in the 7MM + China. Centers such as the California Northstate University and Newcastle University, Guangzhou University of Chinese Medicine, University of Occupational and Environmental Health, etc. were contacted. Their opinion helps to understand and validate current epidemiology trends of Underactive Bladder (UAB) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of UAB, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
A detailed review of the UAB epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
A detailed review of current challenges in establishing the diagnosis.

Underactive Bladder (UAB) Report Insights

Patient Population
Patient population by Etiology
Country-wise Epidemiology Distribution

Report Key Strengths

10 Years Forecast
The 7MM + China Coverage
UAB Epidemiology Segmentation

Underactive Bladder (UAB) Report Assessment

Epidemiology Segmentation
Current Diagnostic Practices

FAQs

What are the disease risks and burdens of UAB epidemiology? What will be the growth opportunities across the 7MM and China with respect to the patient population about UAB epidemiology?
What is the historical and forecasted to UAB epidemiology patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and China?
Which age group is the largest contributor to patients affected with UAB epidemiology?

Reasons to Buy

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.

List of Tables:

List of Table

Table 1: Summary of UAB Epidemiology (2024–2034)

Table 2: Clinical Diagnostic Criteria for Detrusor Underactivity

Table 3: Total Diagnosed Prevalent Cases of UAB in the 7MM + China (2020–2034) (In Thousands)

Table 4: Total Diagnosed Prevalent Cases of LUTS in the US (2020–2034) (In Thousands)

Table 5: Total Diagnosed Prevalent Cases of UAB in the US (2020–2034) (In Thousands)

Table 6: Etiology-specific Diagnosed Prevalent Cases of UAB in the US (2020–2034) (In Thousands)

Table 7: Total Treated Cases of UAB in the US (2020–2034) (In Thousands)

Table 8: Total Diagnosed Prevalent Cases of LUTS in EU4 and the UK (2020–2034) (In Thousands)

Table 9: Total Diagnosed Prevalent Cases of UAB in EU4 and the UK (2020–2034) (In Thousands)

Table 10: Etiology-specific Diagnosed Prevalent Cases of UAB in Germany (2020–2034) (In Thousands)

Table 11: Etiology-specific Diagnosed Prevalent Cases of UAB in France (2020–2034) (In Thousands)

Table 12: Etiology-specific Diagnosed Prevalent Cases of UAB in Italy (2020–2034) (In Thousands)

Table 13: Etiology-specific Diagnosed Prevalent Cases of UAB in Spain (2020–2034) (In Thousands)

Table 14: Etiology-specific Diagnosed Prevalent Cases of UAB in the UK (2020–2034) (In Thousands)

Table 15: Etiology-specific Diagnosed Prevalent Cases of UAB in EU4 and the UK (2020–2034) (In Thousands)

Table 16: Total Treated Cases of UAB in EU4 and the UK (2020–2034) (In Thousands)

Table 17: Total Diagnosed Prevalent Cases of LUTS in Japan (2020–2034) (In Thousands)

Table 18: Total Diagnosed Prevalent Cases of UAB in Japan (2020–2034) (In Thousands)

Table 19: Etiology-specific Diagnosed Prevalent Cases of UAB in Japan (2020–2034) (In Thousands)

Table 20: Total Treated Cases of UAB in Japan (2020–2034) (In Thousands)

Table 21: Total Diagnosed Prevalent Cases of LUTS in China (2020–2034) (In Thousands)

Table 22: Total Diagnosed Prevalent Cases of UAB in China (2020–2034) (In Thousands)

Table 23: Etiology-specific Diagnosed Prevalent Cases of UAB in China (2020–2034) (In Thousands)

Table 24: Total Treated Cases of UAB in China (2020–2034) (In Thousands)

List of Figures:

List of Figures

Figure 1: UAB Classification

Figure 2: Diagnostic Algorithm of UAB

Figure 3: Total Diagnosed Prevalent Cases of UAB in the 7MM + China (2020–2034) (In Thousands)

Figure 4: Total Diagnosed Prevalent Cases of LUTS in the US (2020–2034) (In Thousands)

Figure 5: Total Diagnosed Prevalent Cases of UAB in the US (2020–2034) (In Thousands)

Figure 6: Etiology-specific Diagnosed Prevalent Cases of UAB in the US (2020–2034) (In Thousands)

Figure 7: Total Treated Cases of UAB in the US (2020–2034) (In Thousands)

Figure 8: Total Diagnosed Prevalent Cases of LUTS in EU4 and the UK (2020–2034) (In Thousands)

Figure 9: Total Diagnosed Prevalent Cases of UAB in EU4 and the UK (2020–2034) (In Thousands)

Figure 10: Etiology-specific Diagnosed Prevalent Cases of UAB in EU4 and the UK (2020–2034) (In Thousands)

Figure 11: Total Treated Cases of UAB in EU4 and the UK (2020–2034) (In Thousands)

Figure 12: Total Diagnosed Prevalent Cases of LUTS in Japan (2020–2034) (In Thousands)

Figure 13: Total Diagnosed Prevalent Cases of UAB in Japan (2020–2034) (In Thousands)

Figure 14: Etiology-specific Diagnosed Prevalent Cases of UAB in Japan (2020–2034) (In Thousands)

Figure 15: Total Treated Cases of UAB in Japan (2020–2034) (In Thousands)

Figure 16: Total Diagnosed Prevalent Cases of LUTS in China (2020–2034) (In Thousands)

Figure 17: Total Diagnosed Prevalent Cases of UAB in China (2020–2034) (In Thousands)

Figure 18: Etiology-specific Diagnosed Prevalent Cases of UAB in China (2020–2034) (In Thousands)

Figure 19: Total Treated Cases of UAB in China (2020–2034) (In Thousands)

Tags:

License Type

Offer